GlassScriptPhysician profile
Krishnaveni Gorantla
NPI 1023120805
$614.35
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $60.20 · 2021: $118 · 2022: $18.37.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $144.48 | 2019-2020 | |
| Abbvie INC. | $97.04 | 2019 | |
| Medtronic, INC. | $84.67 | 2021 | |
| Duchesnay USA Incorporated | $67.30 | 2019 | |
| Coopersurgical, INC. | $57.18 | 2019 | |
| Therapeuticsmd, INC. | $43.70 | 2019-2020 | |
| Avion Pharmaceuticals | $38.25 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $26.70 | 2019 | |
| Merck Sharp & Dohme LLC | $19.52 | 2019 | |
| Cordis US Corp. | $18.37 | 2022 | |
| Myovant Sciences INC. | $17.14 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishnaveni Gorantla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.